Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans

Shannon R. Christensen, Sushila A. Toulmin, Trevor Griesman, Lois E. Lamerato, Joshua G. Petrie, Emily T. Martin, Arnold S. Monto, Scott E. Hensley

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA

ABSTRACT

Seasonal influenza viruses are a major cause of human disease worldwide. Most neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the hemagglutinin (HA) protein. Anti-HA head Abs can be highly potent, but they have limited breadth since the HA head is variable. There is great interest in developing new universal immunization strategies that elicit broadly neutralizing Abs against conserved regions of HA, such as the stalk domain. Although HA stalk Abs can provide protection in animal models, it is unknown if they are present at sufficient levels in humans to provide protection against naturally acquired influenza virus infections. Here, we quantified H1N1 HA head- and stalk-specific Abs in 179 adults hospitalized during the 2015–2016 influenza virus season. We found that HA head Abs, as measured by hemagglutinin inhibition (HAI) assays, were associated with protection against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were also associated with protection, but this association was attenuated and not statistically significant after adjustment for HA head-specific Ab titers. We found slightly higher titers of HA stalk-specific IgG1 and IgA Abs in sera from uninfected participants than in sera from infected participants; however, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments, sera from participants with high HAI activity efficiently protected mice, while sera with low HAI activity protected mice to a lower extent. Our data suggest that HA head Abs are more efficient at protecting against H1N1 infection than HA stalk Abs.

IMPORTANCE

Abs targeting the HA head of influenza viruses are often associated with protection from influenza virus infections. These Abs typically have limited breadth, since mutations frequently arise in HA head epitopes. New vaccines targeting the more conserved HA stalk domain are being developed. Abs that target the HA stalk are protective in animal models, but it is unknown if these Abs exist at protective levels in humans. Here, we completed experiments to determine if Abs against the HA head and stalk were associated with protection from naturally acquired human influenza virus infections during the 2015–2016 influenza season.

KEYWORDS

antibody function, antibody repertoire, influenza

Seasonal influenza viruses cause annual epidemics worldwide. Although seasonal influenza vaccines usually provide moderate protection against circulating strains, vaccine effectiveness can be low when there are antigenic mismatches between vaccine strains and circulating strains (1, 2). Additionally, rare yet unpredictable influenza pandemics occur when novel influenza virus strains cross the species barrier and transmit in the human population (3). Antibody (Ab)-mediated immunity is important for protecting against influenza
virus infections (4). The viral membrane protein, hemagglutinin (HA), is the target for most anti-influenza virus neutralizing Abs (5–9). Most neutralizing HA Abs target the HA globular head domain and block virus attachment to sialic acid, the cellular receptor for influenza viruses. However, since the HA head is highly variable, HA head Abs generally exhibit poor cross-reactivity against antigenically drifted viral strains (10). Unlike the head domain, the stalk domain of HA is highly conserved between different influenza virus strains. Abs that target the HA stalk domain can prevent viral replication by inhibiting the pH-induced conformational changes of HA that are required for viral entry into the cell (11). Many HA stalk-specific Abs also protect by blocking HA maturation (11), inhibiting viral egress (12), or mediating Ab-dependent cellular cytotoxicity (ADCC) (13). Although HA stalk Abs are typically subdominant and are not thought to be as efficient as HA head Abs, HA stalk Abs can inhibit diverse influenza strains in vitro (14–17).

Conventional influenza vaccines effectively elicit HA head-reactive Abs but not HA stalk Abs (18). As a result, influenza vaccine effectiveness is dependent on the similarity of the HA head of circulating influenza virus strains and the HA head of vaccine strains (19). Antigenic mismatch between influenza vaccine strains and circulating viral strains have been especially problematic during recent years (20, 21). To circumvent the potential for antigenic mismatch, as well as to prepare against new pandemic viral strains, there is great interest in developing new universal immunization strategies that elicit broadly reactive Abs against conserved regions of HA, such as the stalk domain (22).

HA stalk Abs protect animals from group 1 and group 2 influenza A virus infections (14, 16, 23–29). For example, human anti-HA stalk monoclonal Abs (MAbs) protect mice from lethal pH1N1 infection following prophylactic or therapeutic passive transfers (23, 28) as well as against H5N1 (16, 24, 28) or H7N9 lethal dose challenge (27). Both the prophylactic passive transfer of a human anti-HA stalk MAb or the elicitation of HA stalk-specific Abs by chimeric HA vaccination decreases viral loads in ferrets following pH1N1 infection (25). Additionally, passive transfer of human sera from H5N1 vaccinees protects mice from lethal pH1N1 infection (26), and this protection is likely mediated by HA stalk Abs. Passive transfer of broadly neutralizing HA stalk-specific MAbs against group 2 influenza A viruses also protects mice against heterosubtypic H3 viruses (29) and heterologous H3 and H7 viruses (14). Vaccine strategies designed to elicit HA stalk Abs in humans are currently being pursued (30–32). These strategies include sequential immunizations with chimeric HAs (19, 33), immunization with headless HA antigens (30, 34, 35), and immunizations with mRNA-based vaccines expressing HA (32).

Despite the recent interest in developing new HA stalk-based vaccines, the amount of HA stalk Abs required to protect humans from influenza virus infections and influenza-related disease has not been established. A recent human pH1N1 challenge study demonstrated that HA stalk Ab titers are associated with reduced viral shedding but are not independently associated with protection against influenza infection (36). While human influenza virus challenge studies are valuable, they have some limitations. For example, high doses of virus are used in these studies (37, 38), large numbers of individuals are typically prescreened for certain immunological attributes prior to entering these studies (39), and the pathogenesis of infection differs from that of a natural infection, including key sites of viral replication (38, 40). Serological studies of individuals who naturally acquire influenza virus infections can also be used to identify specific types of Abs that are associated with protection. Here, we present a serological study to determine if serum HA head and stalk Abs are associated with protection against naturally acquired H1N1 infection.

(This article was submitted to an online preprint archive [41].)

RESULTS
Assessment of HA head and stalk Ab association with protection against H1N1 infection. We analyzed sera collected from 179 participants enrolled in a hospital-based study during the 2015–2016 influenza season (Table 1). Adults hospitalized at the
University of Michigan Hospital (Ann Arbor, MI, USA) or Henry Ford Hospital (Detroit, MI, USA) were enrolled according to a case definition of within 10 days of acute respiratory illness onset and subsequently tested for influenza by reverse transcription-PCR (RT-PCR). Serum specimens collected at hospital admission were obtained for estimation of preinfection/early infection antibodies; 58% of specimens included in this analysis were collected within 3 days of illness onset. We analyzed serum samples from 62 hospitalized individuals that had PCR-confirmed H1N1 influenza virus infections. Serum samples from 117 controls were selected from hospitalized individuals that had other respiratory diseases not caused by an influenza virus infection, matching by age category (18 to 49 years, 50 to 64 years, and ≥65 years) and influenza vaccination status.

We quantified serum titers of HA head-specific Abs against the predominant 2015–2016 H1N1 strain using hemagglutination inhibition (HAI) assays. HAI assays detect HA head-specific Abs that prevent influenza virus-mediated cross-linking of red blood cells. We found that HAI titers were associated with protection against H1N1 infection in logistic regression models. We observed a 23.4% reduction in H1N1 infection risk with every 2-fold increase in HAI titer. Previous studies reported that a 1:40 HAI titer is associated with 50% protection from experimental human influenza infections. Consistent with this, over 21% of non-H1N1-infected cases possessed an HAI titer of ≥40, while only ~3% of H1N1-infected cases possessed an HAI titer of >40.

We next quantified relative titers of H1 stalk IgG Abs using enzyme-linked immunosorbent assays (ELISAs) coated with headless H1 proteins. Similar to HAI titers, we found that H1 stalk titers were associated with protection against H1N1 infection in logistic regression models. We observed a 14.2% reduction in H1N1 infection risk with every 2-fold increase in H1 stalk titer. Whereas HAI titers of ≥40 were sharply associated with protection, there was no clear HA stalk IgG titer cutoff that was associated with protection in our study. Samples with the highest HA stalk IgG titers were interspersed among the uninfected and infected groups.

### TABLE 1 Demographic characteristics of subjects enrolled in hospital-based human cohort study

| Parameter | No. (%) of cases<sup>a</sup> | H1N1 infected | H1N1 uninfected |
|-----------|-------------------------------|---------------|-----------------|
| Age       |                               |               |                 |
|          | 18–49 yr                      | 24 (38.7)     | 43 (36.8)       |
|          | 50–64 yr                      | 21 (33.9)     | 39 (33.3)       |
|          | ≥65 yr                        | 17 (27.4)     | 35 (29.9)       |
| Vaccination status |               |               |                 |
|          | Vaccinated                    | 27 (43.5)     | 57 (48.7)       |
|          | Unvaccinated                  | 35 (56.5)     | 60 (51.3)       |
| Sex       |                               |               |                 |
|          | Male                          | 30 (48.4)     | 66 (56.4)       |
|          | Female                        | 32 (51.6)     | 51 (43.6)       |
| Race      |                               |               |                 |
|          | White                         | 35 (56.5)     | 61 (53.5)       |
|          | Black                         | 20 (32.3)     | 37 (31.6)       |
|          | Other/Unknown                 | 7 (11.3)      | 19 (16.2)       |
| Days from illness onset to blood collection |           |               |                 |
|          | ≤3 days                       | 41 (69.5)     | 60 (52.6)       |
|          | >3 days                       | 18 (30.5)     | 54 (47.4)       |

<sup>a</sup>Cases and controls were matched for age group and vaccination status.  
<sup>b</sup>Shown are the number and percentage of each demographic characteristic within the infected and uninfected groups.
Although both HAI titers and HA stalk IgG titers were associated with H1N1 protection in unadjusted models (Table 2), only HAI titers remained statistically associated with protection in adjusted models (Table 2). HA stalk IgG-associated protection lost significance when adjusting for HAI titers; however, the overall reduction in odds of infection for each 2-fold increase in titer remained roughly the same between the unadjusted and adjusted models for both HAI (23.4% to 20.7%) and stalk Ab titers (14.2% to 9.8%), respectively (Table 2).

We completed several experiments to validate our HA stalk IgG data. Headless H1 proteins are engineered to possess only the HA stalk domain and not the HA globular head domain (30). We completed experiments with monoclonal Abs (MAbs) to verify that HA stalk-reactive Abs bind to headless H1 proteins in ELISAs. We found that the H1 head-specific EM-4C04 MAb bound efficiently to a full-length H1 HA protein but failed to bind to our headless H1 protein, while the H1 stalk-specific 70-1F02 MAb bound to each construct similarly (Fig. 2A and B). We used two additional methods to verify that headless HA-based ELISAs accurately quantify HA stalk-reactive Abs. First, we measured Ab binding to a full-length HA chimeric protein that possessed an exotic head domain from an H6 virus fused to the H1 stalk (abbreviated c6/H1) (46). Since H6 viruses have never circulated in the human population, most human Abs that bind to this recombinant HA target the HA stalk domain (19). We found similar relative HA stalk Ab levels when we used the c6/H1 HA-based ELISAs instead of headless HA-based ELISAs (Fig. 2C). We also quantified HA stalk Ab levels using a competition ELISA. For these experiments, we determined the amount of serum Abs that was required to prevent the

**TABLE 2** Logistic regression modeling of HA head and stalk antibody association with protection

| Model                  | Log2 titer P value, OR (95% CI)       |
|------------------------|--------------------------------------|
| HAI only                | 0.0108, 0.766 (0.615, 0.928)          |
| Stalk only              | 0.0417, 0.858 (0.738, 0.992)          |
| HAI + stalk             | 0.0318, 0.793 (0.632, 0.969)          |
| HAI + stalk             | 0.1932, 0.902 (0.769, 1.053)          |

*Logistic regression analyses using both unadjusted (HAI only and stalk only) and adjusted (HAI plus stalk) models. Values represent log2 geometric mean titers from two independent experiments. OR, odds ratio; CI, confidence interval.
binding of a biotinylated HA stalk-specific MAb (70-1F02). The 70-1F02 MAb recognizes a conformationally dependent epitope that spans the HA1 and HA2 subunits (15, 17, 28, 47, 48). We found that 70-1F02-based competition assay titers correlated strongly with the headless HA-based ELISA titers (Fig. 2D).

**Assessment of HA stalk-specific serum Ab isotypes.** Some HA stalk Abs mediate protection through nonneutralizing mechanisms that involve processes such as ADCC (49). IgG1 and IgG3 Ab subtypes are efficient at inducing ADCC, whereas IgG2 and IgG4 are not (50). We quantified relative IgG1, IgG2, and IgG3 HA stalk Abs in serum from a subset of participants using ELISAs coated with headless H1 proteins. In all participants, the majority of HA stalk IgGs were IgG1 (Fig. 3A), consistent with previous reports (51, 52). HA stalk IgG1 Ab titers were slightly higher in uninfected participants than in infected participants (Fig. 3A). Total HA stalk IgG titers closely correlated with HA stalk IgG1 titers (Fig. 3B). Undetectable levels of IgG2 and very low levels of IgG3 HA stalk Abs were detected in serum (Fig. 3A). We did not measure levels of IgG4 HA stalk Abs, since previous studies have shown that IgG4 is not prevalent among anti-influenza virus human Abs (51). It is important to note that titers of each isotype are directly comparable in our experiments, since we used control MAbs in each ELISA (based on

**FIG 2** Validation of headless H1 HA stalk construct. We completed additional ELISAs using the 70-1F02 HA stalk MAb and the EM-4C04 HA head Ab and plates coated with headless HA (A) or full-length HA (B). Graphs depict representative results from two independent experiments. (C) We quantified HA stalk Abs using ELISA plates coated with c6/H1 proteins. HA stalk titers measured by ELISA using c6/H1 or headless HA stalk constructs were tightly correlated ($r = 0.7776, P < 0.0001$, Spearman correlation using log$_2$ geometric mean titers from two independent experiments). (D) We completed competition assays using the conformationally dependent 70-1F02 MAb. 70-1F02 competition titers are tightly correlated with overall HA stalk Ab titers in both infected and uninfected individuals ($r = 0.9097, P < 0.0001$, Spearman correlation using log$_2$ geometric mean titers from two independent experiments). In panels C and D, each circle represents a serum sample from a single individual.
the CR9114 HA stalk MAb [53, 54]) that were engineered to possess the same variable regions coupled to different constant regions.

We next evaluated serum HA stalk IgA Abs, since IgA Abs can be important for controlling respiratory infections. For example, mucosal IgA potently reduces the risk of influenza transmission events in guinea pigs in a dose-dependent manner [55] and suppresses the extracellular release of virus from infected cells [56]. Further, anti-HA stalk MAbs engineered on an IgA backbone neutralize virus more effectively than when they are engineered on an IgG backbone [57]. We did not have access to respiratory secretions, but we did measure levels of HA stalk monomeric IgA in the serum from a subset of participants. Similar to HA stalk IgG1 titers (Fig. 3A), we found that serum HA stalk IgA titers were slightly higher in uninfected participants than in infected participants (Fig. 3A). IgG1 and IgA titers were moderately, though significantly, correlated (Fig. 3C).

**Functionality of Abs from infected and uninfected individuals.** Abs against the HA head and HA stalk can neutralize or limit virus replication through distinct mech-
anisms (11–14, 47–49, 58, 59). For example, most Abs that target epitopes near the receptor binding domain of the HA head block virus binding and neutralize virus \textit{in vitro} and \textit{in vivo} (58). Some HA stalk Abs can directly neutralize virus, but the majority of HA stalk Abs require Fc receptor engagement for protection \textit{in vivo} (15, 49, 60). Neutralizing HA stalk Abs typically inhibit HA conformational changes required to mediate fusion of the virus and cellular membranes (11, 14, 47, 48). Other HA stalk Abs can prevent subsequent viral expansion at later stages of infection by inhibiting HA maturation (11) and viral egress (12).

We completed experiments to assess the \textit{in vitro} and \textit{in vivo} protective potential of serum Abs from a subset of infected and uninfected individuals. First, we performed \textit{in vitro} neutralization assays using green fluorescent protein (GFP)-reporter influenza viruses (61). We generated H1N1 viruses possessing genes encoding enhanced GFP (eGFP) in place of most of the PB1 gene segment. The eGFP segment retained the noncoding and 80 terminal coding nucleotides, allowing this segment to be efficiently and stably packaged into virions. Neutralization assays were completed with these viruses in cell lines that stably expressed PB1. We detected \textit{in vitro} neutralization titers in serum from approximately half of the participants that we tested. We found that \textit{in vitro} neutralization titers were significantly higher in the uninfected group than in the infected group by Welch’s \( t \) test (Fig. 4A). As expected, serum samples with the highest HAI titers had high \textit{in vitro} neutralization titers (Fig. 4B), whereas serum samples with the highest HA stalk titers had more variable \textit{in vitro} neutralization titers (Fig. 4C).

We next completed \textit{in vitro} ADCC assays using serum from a subset of participants. As controls, we also tested MAbs against the HA stalk (CR9114) and HA head (EM-4C04). For these assays, we incubated HA-expressing 293T cells with serum and then added human peripheral blood mononuclear cells (PBMCs). We then measured CD107a (LAMP1) expression on CD3\(^+\) CD56\(^+\) NK cells by flow cytometry. CD107a is a sensitive NK cell degranulation marker whose expression levels strongly correlate with cytokine production and cytotoxicity by NK cells in response to Ab-Fc receptor engagement (62). Consistent with previous studies (53), the CR9114 HA stalk MAb activated NK cells more efficiently than the EM-4C04 HA head MAb (Fig. 4D). Serum samples from participants also activated NK cells, but importantly, we found no differences between NK activation in sera from infected and that from uninfected individuals (Fig. 4D).

Finally, we completed passive transfer experiments in mice. For these experiments we passively transferred human sera into mice that have been engineered to possess human Fc receptors (63) so that we could accurately assess the protective effects mediated by human Fc-FcR interactions. We passively transferred pooled sera from uninfected individuals that had high (>40) HAI titers (abbreviated as uninfected HA\textsuperscript{high}) and uninfected individuals that had low (\( \leq 40 \)) HAI titers (abbreviated as uninfected HA\textsuperscript{low}). We also passively transferred pooled sera from infected individuals, all of whom had low (\( \leq 40 \)) HAI titers (abbreviated as infected HA\textsuperscript{low}). For these experiments, equal volumes of human sera were transferred for each experimental condition. Mice were challenged with a sublethal dose of H1N1 4 h after serum transfer, and body weights were monitored for 15 days (Fig. 5A). Mice that received sera from uninfected HA\textsuperscript{high} participants were fully protected against H1N1 infection. Mice that received sera from HA\textsuperscript{low} participants, whether from uninfected or infected individuals, were moderately protected against H1N1 infection, although these sera conferred significantly less protection than sera from HA\textsuperscript{high} participants (Fig. 5B and Table 3). Since there were different amounts of HA Abs in sera from uninfected HA\textsuperscript{high} participants, uninfected HA\textsuperscript{low} participants, and infected participants (Fig. 5C), it is unclear if the differences in our passive transfer experiments were due to differences in overall HA Ab titers or differences in HA head and stalk Ab ratios. To address this, we repeated passive transfer experiments after adjusting serum amounts so that equal amounts of HA Abs were passively transferred in each experimental group. Similar to what we found in our initial passive transfer experiment, sera from uninfected HA\textsuperscript{high} participants protected mice better than sera from uninfected HA\textsuperscript{low} participants and infected participants (Fig. 5D and Table 4). Interestingly, sera from uninfected HA\textsuperscript{low} participants
protected mice better than sera from infected participants after adjusting serum amounts based on HA Ab titers (Fig. 5D and Table 4). Taken together, these data suggest that human sera with high HAI activity efficiently protect in vivo, while human sera with low HAI activity also protect in vivo, albeit to a lower extent.

**DISCUSSION**

Observational studies can be useful in identifying Ab types that are associated with protection from influenza virus infection. Here, we found that both HA head and stalk Abs appeared to be associated with preventing H1N1 hospitalizations during the 2015–2016 season. We found that the effect size of HAI-associated protection (23.4% reduced risk of infection for every 2-fold increase in titer) was larger than the effect size of HA stalk Ab-associated protection (14.2% reduced risk of infection for every 2-fold increase in titer).
increase in titer). In our study, HAI titers were independently associated with protection in adjusted models; however, HA stalk Abs were not. However, the effects of both HAI and HA stalk Ab titers were only slightly attenuated in our adjusted model, and it is possible that our relatively small sample size limited our ability to detect an independent association between HA stalk titers and protection.

There are several limitations to our study. Since our sample size was relatively small, we only evaluated the contribution of Abs to the HA head and stalk. Larger studies will be required to independently evaluate other immune correlates of protection. For example, it will be important for future studies to evaluate the relationship between HA head and stalk Ab-associated protection and neuraminidase (NA) Ab-associated pro-
## TABLE 3 One-way ANOVA results for passive transfer normalized by volume

| Comparison                      | Result by dpi | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  |
|--------------------------------|---------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| PBS vs uninfected HAI<sup>high</sup> | 0.9535, NS    | 0.8290, NS | 0.2205, NS | 0.0133<sup>*</sup> | 0.0094<sup>**</sup> | <0.0001<sup>***</sup> | <0.0001<sup>****</sup> | <0.0001<sup>****</sup> | <0.0001<sup>****</sup> | <0.0001<sup>****</sup> | <0.0001<sup>****</sup> | 0.0004<sup>****</sup> | 0.0048<sup>****</sup> | 0.0175<sup>****</sup> |
| PBS vs uninfected HAI<sup>low</sup> | 0.7722, NS    | 0.6513, NS | 0.1259, NS | 0.022<sup>**</sup> | 0.0013<sup>**</sup> | 0.0017<sup>**</sup> | 0.0017<sup>**</sup> | 0.0094<sup>**</sup> | 0.0070<sup>**</sup> | 0.0028<sup>**</sup> | 0.0062<sup>**</sup> | 0.0688, NS | 0.0757, NS | 0.2567, NS | 0.3884, NS |
| PBS vs infected HAI<sup>low</sup>  | 0.9840, NS    | 0.9535, NS | 0.5620, NS | 0.8066, NS | 0.4905, NS | 0.2181, NS | 0.5920, NS | 0.7775, NS | 0.0543, NS | 0.0356<sup>*</sup> | 0.0150<sup>**</sup> | 0.0570, NS | 0.1593, NS | 0.4164, NS | 0.5456, NS |
| Uninfected HAI<sup>high</sup> vs uninfected HAI<sup>low</sup> | 0.7604, NS    | 0.9938, NS | 0.9967, NS | 0.9897, NS | 0.9466, NS | 0.1707, NS | 0.0020<sup>***</sup> | 0.0001<sup>***</sup> | 0.0008<sup>**</sup> | 0.0069<sup>**</sup> | 0.0709, NS | 0.0480<sup>**</sup> | 0.1517, NS | 0.2574, NS | 0.3808, NS |
| Uninfected HAI<sup>high</sup> vs infected HAI<sup>low</sup> | 0.9728, NS    | 0.9839, NS | 0.8833, NS | 0.1011, NS | 0.0173<sup>**</sup> | 0.0012<sup>**</sup> | <0.0001<sup>****</sup> | <0.0001<sup>****</sup> | 0.0003<sup>***</sup> | 0.0228<sup>**</sup> | 0.0422<sup>**</sup> | 0.0558, NS | 0.1218, NS | 0.2207, NS |
| Uninfected HAI<sup>low</sup> vs infected HAI<sup>low</sup> | 0.9312, NS    | 0.9155, NS | 0.7605, NS | 0.1609, NS | 0.0512, NS | 0.1735, NS | 0.4706, NS | 0.7751, NS | 0.7989, NS | 0.6871, NS | 0.9693, NS | >0.9999, NS | 0.9869, NS | 0.9869, NS | 0.9886, NS |

<sup>a</sup>One-way ANOVA with Tukey’s correction for multiple comparisons performed for each day postinfection. The p value for each comparison is reported, calculated on the percent weight lost compared to the baseline for each group each day. Data in this table are depicted in Fig. 5B. NS, not significant. *, p = 0.05; **, p = 0.01; ***, p = 0.001; ****, p = 0.0001.
TABLE 4 One-way ANOVA results for passive transfer normalized by HA titera

| Comparison          | Result by dpi |
|---------------------|---------------|
|                     | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 |
| PBS vs uninfected HAIhigh | 0.7715, NS | 0.1346, NS | 0.5014, NS | 0.1318, NS | 0.0005*** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** |
| PBS vs uninfected HAIlow | 0.4401, NS | 0.9592, NS | 0.8064, NS | 0.3562, NS | 0.0851, NS | 0.0034** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** |
| PBS vs infected HAIlow | 0.0727, NS | 0.2528, NS | 0.7643, NS | 0.3626, NS | 0.4106, NS | 0.8007, NS | 0.2705, NS | 0.0039** | 0.0001*** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | 0.0001*** | 0.0004*** |
| Uninfected HAIhigh vs uninfected HAIlow | 0.9413, NS | 0.0516, NS | 0.9513, NS | 0.9271, NS | 0.1217, NS | 0.1124, NS | 0.0920, NS | 0.0210* | 0.0283* | 0.0335* | 0.1813, NS | 0.0442* | 0.1948, NS | 0.5458, NS | 0.5089, NS |
| Uninfected HAIhigh vs infected HAIlow | 0.3752, NS | 0.0023** | 0.1100, NS | 0.0038** | <0.0001*** | <0.0001**** | <0.0001**** | <0.0001**** | <0.0001**** | 0.0005** | <0.0001**** | 0.0023** | 0.0047** | 0.0225, NS |
| Uninfected HAIlow vs infected HAIlow | 0.7028, NS | 0.5014, NS | 0.2722, NS | 0.0151* | 0.0028** | 0.0004*** | <0.0001**** | 0.0011** | 0.0051** | 0.0111* | 0.0573, NS | 0.0353* | 0.1734, NS | 0.0803, NS | 0.3097, NS |

aOne-way ANOVA with Tukey’s correction for multiple comparisons performed for each day postinfection. The P value for each comparison is reported, calculated on the percent weight lost compared to the baseline for each group each day. Data in this table are depicted in Fig. 5D. NS, not significant. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.
tection. Recent studies have shown that NA Abs are associated with protection in an H1N1 challenge cohort (36), and NA Abs were also identified as an independent correlate of protection in a controlled vaccine efficacy study (64). It will be critical to determine if NA Ab-associated protection is independent of the protective effects of HA head and stalk Abs.

It should be noted that participants in our study were likely admitted to the hospital at various days postinfection. While most blood specimens were collected relatively early (≤3 days after symptom onset), we cannot exclude that some participants in our studies were infected for a prolonged period of time before being admitted to the hospital. This raises the possibility that some participants have already mounted de novo Ab responses to H1N1 infection, which could convolute the analyses of Ab types associated with protection. While this is a possibility, it is less of a concern since we found that all infected individuals have very low HAI titers. If our infected participants were making de novo Ab responses, we would anticipate that some of them would have high HAI titers to the infecting H1N1 virus. In addition, Ab titers do not typically increase as days from symptom onset to blood specimen collection increases (42), which suggests that samples used in this study were collected prior to the generation of de novo Ab responses against the infecting virus.

It is interesting that in vitro neutralization titers (Fig. 4A), but not ADCC titers (Fig. 4D), were associated with H1N1 protection. In vitro neutralization activity is mainly driven by HA head Abs (5–9), whereas HA stalk Abs are more effective at ADCC (49). It should be noted that HA stalk IgG1 and IgA Abs have been shown to mediate phagocytosis with innate cellular partners (65), which could prove to be an important mechanism of protection by HA stalk Abs and should be considered in future studies. HA head Abs were associated with greater protection in our cohorts than stalk Abs (Table 2), and these Abs conferred protection superior to that of HA stalk Abs when passively transferred into mice (Fig. 4B and D). Interestingly, serum from HAI<sub>low</sub> uninfected participants protected mice better than serum from HAI<sub>low</sub> infected participants in passive transfer studies after normalizing total HA Ab amounts under each transfer condition. While these data suggest that HA stalk Abs can confer protection in vivo, we cannot rule out that other immune components (such as NA Abs) contributed to protection in these experiments.

Taken together, our findings provide important new insights into the prevalence and functionality of HA head and stalk Abs in humans. Future studies that tease out the interdependence of HA head and stalk Abs, as well as Abs and T cells against other viral antigens, will be useful in guiding the development of new universal influenza vaccine antigens.

**MATERIALS AND METHODS**

*Human subjects.* During the 2015–2016 influenza season, adult (≥18 years) patients hospitalized for treatment of acute respiratory illnesses at the University of Michigan Hospital in Ann Arbor, MI, and Henry Ford Hospital in Detroit, MI, were prospectively enrolled in a case test-negative design study of influenza vaccine effectiveness. All participants provided informed consent and were enrolled ≤10 days from illness onset during the period of influenza circulation (January to April of 2015 and 2016). Participants completed an enrollment interview and had throat and nasal swab specimens collected and combined for influenza virus identification. Influenza vaccination status was defined by self-report and documentation in the electronic medical record and Michigan Care Improvement Registry (MCIR). When available, clinical serum specimens collected as early as possible after hospital admission were retrieved; all specimens were collected ≤10 days from illness onset based on the enrollment case definition. Studies involving humans were approved by the Institutional Review Boards of the University of Michigan and University of Pennsylvania. All experiments (HAI, ELISAs, in vitro neutralization assays, ADCC assays, and passive transfers) were completed at the University of Pennsylvania using deidentified sera.

*Viruses.* Viruses possessing A/California/07/2009 HA and NA or A/HUP/04/2016 HA and NA were generated by reverse genetics using internal genes from A/Puerto Rico/08/1934. Viruses were engineered to possess the Q226R HA mutation, which facilitates viral growth in chicken eggs. Viruses were grown in fertilized chicken eggs, and the HA gene was sequenced to verify that additional mutations did not arise during propagation. We isolated the A/HUP/04/2016 virus from respiratory secretions obtained from a patient at the Hospital of the University of Pennsylvania in 2016. For this process, deidentified clinical material from the Hospital of the University of Pennsylvania Clinical Virology Laboratory was added to Madin-Darby canine kidney (MDCK) cells (originally obtained from the National Institutes of
were performed in 96-well U-bottom plates (no. 353077; Corning). Sera were initially diluted 2-fold and followed by hemadsorption, in accordance with WHO recommended protocols (Seiken) and stored in aliquots at -80°C. Plasmids encoding the recombinant chimeric (c6/H1) HA were provided by Florian Krammer (Mt. Sinai). The detailed protocol for expression of this protein is published elsewhere (46). In brief, the c6/H1 HA protein was expressed in High Five baculovirus cells and purified using the same methods referenced for the headless HA stalk protein. Purified protein was exchanged into PBS (no. 21-031-CM; Corning) and stored in aliquots at -80°C.

**Mabs.** Plasmids encoding the human MAb EM-4C04, 70-1F02, and CR9114 IgG1 isotypes were provided by Patrick Wilson at the University of Chicago. The heavy-chain constant regions for IgG2, IgG3, and IgA (sequences listed below) were synthesized as a gBlock by IDT and cloned into the pSport6 vector containing the heavy chain of CR9114. All Mabs were expressed in 293T cells and purified 4 days postinfection using NAb protein A/G spin kits (no. 89950; Thermo Fisher) for the IgG isotypes or peptide M isotype (no. gel-pdm-2; InvivoGen) for the IgA isotype. The IgG2 sequence is CGCATGATGCGTCGACCAAAGGGTCCTAGCGTTTTCCGCTCGCACCTTGTAGTCGGTGTTGATAAATCCAGGTGGCAGCAAGGAAATGTTTTCTCTTGTTCAGTGATGCATGAGGCGCTCCACAACCATTTCAACCGGAGAACAATTACAAAACGACACCGCCCATGCTTGATAGTGATGGTTCCTTCTTCTTGTACAGCAAGTTGACCAAGCAGAAGACTAAACCGAGAGAGGAACAGTATAATAGCACATTCCGGGTTGTTTCCGTACTTACAGTACTTCGGTGAGGTATGGAGGTGGTATGTAGATGGCGTTGAAGTGCATAATGCAAACGACAAAGGGACAGCAGACCGACACGACAGGTTGATACCCCGCCGCCGTGTCCTCGCTGTCCGGAAACCAAAGCTGTGATACCCCCCCACCTTACCAAGGTTGATAAGAGGGTTGAGCTTAAAACACCGCTTGGTGACACAACCCATACGTGTCCAAGATGTCCGGAAGCGTTGTTACCGTACCATCCAGTAGCCTTGGCACCCAGACCTACACCTGTAATGTTAATCACAAACCAAGTAACAGTGGGGCATTGACGTCTGGCGTTCATACTTTTCCGGCAGTACTTCAGAGTTCCGGCCTTTATTCTTTGCAATGGCAGGCGGCACCGCGGCGTTGGGATGTCTTGTCAAGGATTATTTTCCCGAACCCGTCACCGTAAGCTGTTACGCAAAAATCACTCTCACTTTCACCGGGGAAATGAAGCTTGAGCAGGGCCT.

The IgG3 sequence is CGCATGATGCGTCGACCAAAGGGGCAGCCTCATCTTCCGGCTCTTGATGCTGTTAGAAGATTTTTCGCGCGGAGGAGCTAGTTGCCATGATGAGGCGCTCCATCHACATTTCAACCGGAGAACAATTACAAAACGACACCGCCCATGCTTGATAGTGATGGTTCCTTCTTCTTGTACAGCAAGTTGACCAAGCAGAAGACTAAACCGAGAGAGGAACAGTATAATAGCACATTCCGGGTTGTTTCCGTACTTACAGTACTTCGGTGAGGTATGGAGGTGGTATGTAGATGGCGTTGAAGTGCATAATGCAAACGACAAAGGGACAGCAGACCGACACGACAGGTTGATACCCCGCCGCCGTGTCCTCGCTGTCCGGAAACCAAAGCTGTGATACCCCCCCACCTTACCAAGGTTGATAAGAGGGTTGAGCTTAAAACACCGCTTGGTGACACAACCCATACGTGTCCAAGATGTCCGGAAGCGTTGTTACCGTACCATCCAGTAGCCTTGGCACCCAGACCTACACCTGTAATGTTAATCACAAACCAAGTAACAGTGGGGCATTGACGTCTGGCGTTCATACTTTTCCGGCAGTACTTCAGAGTTCCGGCCTTTATTCTTTGCAATGGCAGGCGGCACCGCGGCGTTGGGATGTCTTGTCAAGGATTATTTTCCCGAACCCGTCACCGTAAGCTGTTACGCAAAAATCACTCTCACTTTCACCGGGGAAATGAAGCTTGAGCAGGGCCT.

The IgA sequence is CGCATGATGCGTCGACCAAAGGGGCAGCCTCATCTTCCGGCTCTTGATGCTGTTAGAAGATTTTTCGCGCGGAGGAGCTAGTTGCCATGATGAGGCGCTCCATCHACATTTCAACCGGAGAACAATTACAAAACGACACCGCCCATGCTTGATAGTGATGGTTCCTTCTTCTTGTACAGCAAGTTGACCAAGCAGAAGACTAAACCGAGAGAGGAACAGTATAATAGCACATTCCGGGTTGTTTCCGTACTTACAGTACTTCGGTGAGGTATGGAGGTGGTATGTAGATGGCGTTGAAGTGCATAATGCAAACGACAAAGGGACAGCAGACCGACACGACAGGTTGATACCCCGCCGCCGTGTCCTCGCTGTCCGGAAACCAAAGCTGTGATACCCCCCCACCTTACCAAGGTTGATAAGAGGGTTGAGCTTAAAACACCGCTTGGTGACACAACCCATACGTGTCCAAGATGTCCGGAAGCGTTGTTACCGTACCATCCAGTAGCCTTGGCACCCAGACCTACACCTGTAATGTTAATCACAAACCAAGTAACAGTGGGGCATTGACGTCTGGCGTTCATACTTTTCCGGCAGTACTTCAGAGTTCCGGCCTTTATTCTTTGCAATGGCAGGCGGCACCGCGGCGTTGGGATGTCTTGTCAAGGATTATTTTCCCGAACCCGTCACCGTAAGCTGTTACGCAAAAATCACTCTCACTTTCACCGGGGAAATGAAGCTTGAGCAGGGCCT.
then added to four agglutinating doses of virus, for a final volume of 100 µl/well. Turkey erythrocytes (no. 7209401; Lampire) were added to each well (12.5 µl diluted to 2%, vol/vol). The erythrocytes were gently mixed with sera and virus and then allowed to incubate for 1 h at room temperature. Agglutination was read and HA1 titers were expressed as the inverse of the highest dilution that inhibited four agglutinating doses of virus. Each HA1 assay was performed independently on two different days.

**Headless HA ELISAs.** Headless HA ELISAs were performed on 96-well Immulon 4HBX flat-bottom microtiter plates (no. 3855; Thermo Fisher) coated with 0.5 µg/well of streptavidin (no. S4762; Sigma). We completed total IgG headless HA ELISAs with all serum samples and isotype headless HA ELISAs with serum samples that had sufficient volumes. Biotinylated headless HA protein was diluted in biotinylation buffer containing 1X Tris-buffered saline (TBS; no. 170-6435; Bio Rad), 0.005% Tween (no. 170-6531; Bio Rad), and 0.1% bovine serum albumin (no. A8022; Sigma) to 0.25 µg/ml, and 50 µl was added per well and incubated on a rocker for 1 h at room temperature. Each well was then blocked for an additional 1 h at room temperature using biotinylation blocking buffer containing 1X TBS (no. 170-6435; Bio Rad), 0.005% Tween 20 (no. 170-6531; Bio Rad), and 1% bovine serum albumin (no. A8022; Sigma). Each serum sample was serially diluted in biotinylation buffer (starting at 1:100 dilution for total IgG or 1:50 dilution for Ab isotype), added to the ELISA plates, and allowed to incubate for 1 h at room temperature on a rocker. As a control, we added the human CR9114 stalk-specific MAb, starting at 0.03 µg/ml, to verify equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson), peroxidase-conjugated mouse anti-human IgG1 (no. 9054-05; Southern Biotech), peroxidase-conjugated mouse anti-human IgG2 (no. 9060-05; Southern Biotech), peroxidase-conjugated mouse anti-human IgG3 (no. 9210-05; Southern Biotech), or peroxidase-conjugated goat anti-human IgA (no. 2050-05; Southern Biotech) was incubated for 1 h at room temperature on a rocker. Finally, SureBlue TMB peroxidase substrate (no. S120-0077; KPL) was added to each well, and the reaction was stopped with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) next was incubated for 1 h at room temperature. Finally, SureBlue TMB peroxidase substrate (no. S120-0077; KPL) was added to each well, and the reaction was stopped with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) next was incubated for 1 h at room temperature. Finally, SureBlue TMB peroxidase substrate (no. S120-0077; KPL) was added to each well, and the reaction was stopped with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) between each step using a BioTek 405 LS microplate washer. Relative titers were determined using a consistent concentration of the CR9114 MAb for each plate and reported as the corresponding inverse of the serum dilution that generated the equivalent optical densities (OD). Each type of ELISA (total IgG, IgG1, IgG2, IgG3, and IgA) was performed twice.

**Chimeric (c6/H1) HA ELISAs.** Chimeric HA ELISAs were performed on 96-well Immulon 4HBX flat-bottom microtiter plates (no. 3855; Thermo Fisher). HA proteins were diluted in PBS (no. 21-031-CM; Corning) to 2 µg/ml and coated at 50 µl per well overnight at 4°C. Plates were blocked using an ELISA buffer containing 3% goat serum (no. 16210-064; Gibco), 0.5% milk (no. DSM17200-1000; Dot Scientific, italic), H9262 g/ml, to verify equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson) was incubated for 1 h at room temperature. Next was incubated for 2 h at room temperature. As a control, we added the human CR9114 stalk-specific MAb, starting at 0.03 µg/ml, to verify equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson) was incubated for 1 h at room temperature. Finally, SureBlue TMB peroxidase substrate (no. S120-0077; KPL) was added to each well, and the reaction was stopped with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) between each step using a BioTek 405 LS microplate washer. Relative titers were determined using a consistent concentration of the CR9114 MAb for each plate and reported as the corresponding inverse of the serum dilution that generated the equivalent OD. Each ELISA was performed twice.

**Competition ELISAs.** Competition ELISAs were performed on 96-well Immulon 4HBX flat-bottom microwell plates (no. 3855; Thermo Fisher). HA proteins were diluted in PBS (no. 21-031-CM; Corning) to 2 µg/ml and coated at 50 µl per well overnight at 4°C. Plates were blocked using the biotinylation blocking buffer, described earlier, for 2 h at room temperature. Each serum sample was serially diluted in the ELISA buffer (starting at 1:100 dilutions), added to the ELISA plates, and allowed to incubate for 2 h at room temperature. As a control, we added the human CR9114 stalk-specific MAb, starting at 0.03 µg/ml, to verify equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson) was incubated for 1 h at room temperature. Finally, SureBlue TMB peroxidase substrate (no. S120-0077; KPL) was added to each well, and the reaction was stopped with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) between each step, with the exception of the addition of biotinylated 70-1F02, using a BioTek 405 LS microplate washer. Relative titers were determined using the uncontrolled competition lane OD (biotinylated 70-1F02 binding in the absence of sera) and setting that OD to 100%. Each serum sample was then assessed by nonlinear regression using GraphPad Prism. Titers are reported as the inverse of the highest serum dilution that inhibited binding of the biotinylated 70-1F02 to 30% of the uncontrolled binding. Each competition ELISA was performed independently on two different days.

**In vitro neutralization assays.** In vitro neutralization assays were performed using a subset of samples. We excluded samples that had limited amounts of sera. Plasmids encoding pH1N1 viruses possessing genes encoding eGFP in place of most of the PB1 gene segment were provided by Jesse Bloom at The Fred Hutchinson Cancer Research Center. The eGFP segment retained the noncoding and 80 terminal coding nucleotides, allowing this segment to be efficiently and stably packaged into the...
Recombinant viruses have been published elsewhere (April 2019 Volume 93 Issue 8 e02134-18).

A master mix and the aliquots for the various controls were plated at 50 to 10^5 cells/ml was set up using complete RPMI medium. Aliquots of the PBMC master mix were loosened by pipetting and transferred to a 96-well U-bottom plate (no. 353077; Corning) and spun down for 1 min at 1,200 rpm, and the medium was flicked out. The serum/MAb dilutions were transferred were loosened by pipetting and transferred to a 96-well U-bottom plate (no. 353077; Corning) and spun down for 1 min at 1,200 rpm, and the medium was flicked out. Serum (FBS; no. F0926-100; Sigma), 0.3% bovine serum albumin (no. A8022; Sigma), and 25 mM HEPES (no. 25-060-C; Corning), beginning at a 1:80 dilution. PB1flank-eGFP viruses were then added to the serum dilutions and were incubated at 37°C for 1 h to allow for neutralization. As a control, the human CR9114 HA stalk-specific MAb was added to ensure equal infectivity and neutralization across all plates. Viruses and sera then were transferred to 96-well flat-bottom tissue culture plates containing 80,000 cells per well of MDCK-SIAT1-TMRPR522 cells constitutively expressing PB1 under a cytomegalo-virus promoter. Plates were incubated at 37°C for 30 h postinfection. Mean fluorescent intensity of samples was read using an Envision plate reader (monochromator, top read, excitation filter at 485 nm, emission filter at 530 nm). Neutralization titers were reported as the inverse of the highest dilution that decreased mean fluorescence by 90% relative to infected control wells in the absence of antibodies. Each neutralization assay was performed independently on two different days.

**ADCC activity assays.** ADCC activity assays were completed using a subset of samples. We excluded samples that had limited amounts of sera. 293T cells were plated at 3.5e4 cells per well in a 96-well flat-bottom tissue culture plate (no. 353072; Corning) 24 h before transfection. 293T cells were then transfected using 20 μl Opti-MEM (no. 31985-070; Gibco), 1 μl Lipofectamine 2000 (no. 11668-019; Invitrogen), and 500 ng plasmids encoding the HA gene from A/California/07/09 per well and incubated at 37°C for approximately 30 h before performing the ADCC assay. Approximately 12 h before performing the ADCC assay, frozen PBMCs from four separate donors (obtained through the University of Pennsylvania Human Immunology Program) were thawed at 37°C and then washed 3× using 15 ml of warmed complete RPMI medium (no. 10-040-CM; Corning) (supplemented with 10% heat-inactivated FBS [no. F0926-100; Sigma], 1% penicillin-streptomycin [no. 30-002-CI; Corning]). Each aliquot of PBMCs was then transferred to a 50-ml conical tube and rested overnight in 23 ml of complete RPMI medium at a 5° angle, with the cap loosened to allow for gas exchange. On the day of the assay, serum samples were diluted in Dulbecco's modified Eagle's medium (no. 10-013-CM; Corning) supplemented with 10% FBS (no. F0926-100; Sigma) at a 1:10 dilution. As a control for this assay, the human CR9114 HA stalk-specific MAb was included at a concentration of 5 μg/ml to ensure efficient activation of ADCC. Transfected 293T cells were loosened by pipetting and transferred to a 96-well U-bottom plate (no. 353077; Corning) and spun down for 1 min at 1,200 rpm, and the medium was flicked out. The serum/MAb dilutions were transferred to the 293T cells and were mixed with the transfected cells by gentle pipetting and incubated at 37°C for 2 h. PBMC aliquots were combined, spun down, and counted, and a master mix of 267 cells/ml was set up using complete RPMI medium. Aliquots of the PBMC master mix were set up for the live/dead and unstained control wells. Phycoerythrin-conjugated mouse anti-human CD107α (no. 328608; BioLegend) was added at a 1:50 dilution. Brefeldin A (no. B7651; Sigma) was added to 10 μg/ml Monensin (no. 51-2092K2; BD BioSciences) was added to 5 μl per 1 ml of PBMC master mix concentration. An aliquot of 200 μl was made, phorbol myristate acetate (no. P1585; Sigma) was added to a 5 μg/ml concentration, and ionomycin (no. I9657; Sigma) was added to a 1 μg/ml concentration. Serum/cell suspensions were spun down at 1,200 rpm for 1 min, and medium was flicked out. The PBMC master mix and the aliquots for the various controls were plated at 50 μl per well and mixed gently by pipetting, followed by incubation at 37°C for 4 h. Cells were then stained in the following manner. Live/dead fixable near-infrared stain (no. L34976; Thermo) was diluted 1:50 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) for 30 min in the dark at 4°C. Human FcR blocking reagent (no. 130-059-901; Miltenyi Biotec) was diluted 1:25 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) and incubated in the dark for 1 min at 4°C. Alexa Fluor 647-conjugated mouse anti-human-CD3 (no. 344826; BioLegend) and BV421-conjugated mouse anti-human CD56 (no. 318328; BioLegend) were diluted 1:200 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) and incubated in the dark for 1 min at 4°C. Live/dead fixable near-infrared stain (no. L34976; Thermo) was diluted 1:50 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) and incubated in the dark for 30 min at room temperature. Cells were then fixed using 10% paraformaldehyde (no. 15714-S; Electron Microscopy Sciences) diluted in 1% paraformaldehyde (no. 15714-S; Electron Microscopy Sciences) diluted in MilliQ water for 6 min at room temperature. Cells were extensively washed with DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) between each step. Cells were stored overnight at 4°C in 100 μl/well of DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma).

Flow cytometry was performed using and LSRII (BD Biosciences, San Diego, CA). Compensation controls were set up using anti-mouse IgGk beads (no. S52843; BD Biosciences) and run for each antibody for every experiment, and voltages were adjusted accordingly. All data were analyzed in FlowJo (Ashland, OR) by gating on single cells that were CD3− CD56− CD107α+ in control wells that did not contain serum/MAb to adjust for basal levels of CD107α expression. These gates were then applied to each serum sample, and ADCC activity was expressed as a percentage of NK cells expressing CD107α+. Each ADCC assay was performed independently on three different days, and the same four PBMC donors were pooled and used for each replicate.

**Murine experiments.** All mouse experiments were reviewed and approved by the IACUCs of the Wistar Institute and University of Pennsylvania. All passive transfer experiments were performed in in humanized FcγR mice (FcγRγ[1, 2a, 2b, 3a, 3b]gt/mFcγR alpha chain [1, 2, 3, 4]−/−) that were provided by Jeffrey Ravetch at the Rockefeller University (63). Sera were pooled into three groups, uninfected HAINS (≥ 40 HAI titer), uninfected HAINS (≤ 40 HAI titer), and infected HAINS (≤ 40 HAI titer), and then heat treated for 30 min at 55°C. Serum or sterile PBS was then transferred into mice by intraperitoneal injection. Four hours posttransfer, mice were bled by submandibular puncture, anesthetized using...
isoflurane, and challenged intranasally using 50 μl of sterile PBS containing a sublethal dose (9×4 50% tissue culture infective dose units) of A/California/07/09. ELISAs were run on the sera collected from each animal to verify that the passive transfer was successful. Mice were weighed on the day on infection and then daily for 15 days postinfection. Weight loss was reported as percent weight loss relative to the starting weight of each mouse. For the passive transfer normalized by volume, two independent experiments were performed using a mix of male and female humanized FcR mice for a total of 6 mice per group per experiment. For the passive transfer normalized by HA antibody titer, a single experiment was performed using a mix of male and female humanized FcR mice for a total of 6 mice per group, since we had limited amounts of sera available for this study. One-way analysis of variance (ANOVA) was performed for each day postinfection between groups using GraphPad Prism software.

**Statistical analysis.** Fisher’s exact tests, one-way ANOVAs, and Welch’s t tests were completed using GraphPad software. Both unadjusted and adjusted logistic regression analyses were performed using R Studio (version 1.0.153).

**ACKNOWLEDGMENTS**

This work was supported by the National Institute of Allergy and Infectious Diseases (1R01AI113047, S.E.H.; 1R01AI108686, S.E.H.; 1R01AI097150, A.S.M.; CEIRS HHSN272201400005C, S.E.H. and A.S.M.; TL1TR001880, S.R.C.) and the Centers for Disease Control and Prevention (U01IP000474, A.S.M.). S.E.H. holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.

We thank Florian Krammer (Mt. Sinai), Jesse Bloom (Fred Hutchinson Cancer Center), Patrick Wilson (University of Chicago), Barney Graham (Vaccine Research Center, NIH), and Adrian McDermott (Vaccine Research Center, NIH) for providing plasmids for this study. We thank Jeffrey Ravetch (Rockefeller University) for providing breeding pairs of humanized FcR mice.

A.S.M. has received consultancy fees from Sanofi Pasteur, Seqirus, and Novavax for work unrelated to this report. S.E.H. has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. All other authors have no potential conflicts to declare.

**REFERENCES**

1. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, Green HK, Cottrell S, Johnston J, de Lusignan S, Moore C, Gunson R, Robertson C, McMenemy J, Zambon M. 2015. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill 20:21025.

2. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwinnd TL, Martineau C, Eshaghi A, Bastien N, Li Y. 2015. Interim estimates of 2014/15 vaccine effectiveness against influenza A/H3N2 from Canada’s Physician Surveillance Network, January 2015. Euro Surveill 29:21022.

3. Johnson NP, Mueller J. 2002. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 76:105–115. https://doi.org/10.1353/bhm.2002.0022.

4. Webster RG, Warburton F, Lamb RA. 2013. Textbook of influenza, 2nd ed. Wiley-Blackwell, Chichester, West Sussex, United Kingdom.

5. Victora GD, Wilson PC. 2015. Germinal center selection and the antibody response to influenza. Cell 163:545–548. https://doi.org/10.1016/j.cell.2015.03.004.

6. Eisen AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 haemagglutinin (H1 subtype). Cell 31:417–427. https://doi.org/10.1016/0092-8674(82)90135-0.

7. Gerhard W, Yewdell JW, Frankel ME, Webster R. 1981. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290:713–717. https://doi.org/10.1038/290713a0.

8. Angeletti D, Gibbs JS, Angel M, Kosik I, Hickman HD, Frank GM, Das SR, Wheatley AK, Prabhakaran M, Leggat DJ, McDermott AB, Yewdell JW. 2017. Defining B cell immunodominance to viruses. Nat Immunol 18:456–463. https://doi.org/10.1038/ni.3680.

9. Altman MO, Bemmink JR, Yewdell JW, Herrin BR. 2015. Lampey VLBB response to influenza virus supports universal rules of immunogenicity and antigenicity. Elife 4:e07467. https://doi.org/10.7554/eLife.07467.

10. Krammer F, Palese P. 2013. Influenza virus haemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521–530. https://doi.org/10.1016/j.co viro.2013.07.007.

11. Brandenburg B, Koudstaal W, Goudsmidt J, Klaren V, Tang C, Bijnv MY, Korse HJ, Kwaks T, Otterstorm JJ, Jurasek J, van Oijen AM, Vogels R, Friesen RH. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. https://doi.org/10.1371/journal.pone.0080034.

12. Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. 2014. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol 88:13580–13592. https://doi.org/10.1128/JVI.02289-14.

13. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167–182. https://doi.org/10.1038/nrd4529.

14. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Braenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmidt J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843–850. https://doi.org/10.1126. science.1204839.

15. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Varchieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giachetto-Sasselli I, Calder L, Sallusto F, Cozzari P, Haire LF, Tempert N, Langedijk JP, Skelhel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850–856. https://doi.org/10.1126.science.1205669.

16. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke JT, Torres-Velez FJ, Tempert NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Investig 120:1663–1673. https://doi.org/10.1172/JCI41902.

17. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B,
17. Wang TT, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, Garcia-Sastre A, Palese P, Treanor JJ, Krammer F. 2013. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 87:4728–4737. https://doi.org/10.1128/JVI.03509-12.

18. Nachbagauer R, Krammer F. 2017. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect 23:222–228. https://doi.org/10.1016/j.cmi.2017.02.009.

19. Nachbagauer R, Albrecht RA, Takahashi K, Krammer F. 2012. Expression of functional recombinant HA antibodies in humans and mice. J Virol 86:7574–7581. https://doi.org/10.1128/JVI.02305-12.

20. Nachbagauer R, Krammer F, Treanor JJ, Albrecht RA, Palese P. 2014. Influenza virus vaccines expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774–5781. https://doi.org/10.1128/JVI.00137-12.

21. Steel J, Lowen AC, Wang TT, Yondola M, Durrell M, Albrecht RA, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. https://doi.org/10.1128/mBio.00018-10.

22. Balasingam S, Wilder-Smith A. 2016. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis 49:69-70. https://doi.org/10.1016/j.ijid.2016.03.007.

23. Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Martin JS, Delmore A,Blocked K, Fergu-son SE, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273. https://doi.org/10.1038/nsmb.1566.

24. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, Li Z, Zhou L, Shen J, Tang S, Krammer F. 2014. Broadly protective monoclonal antibodies against H3 influenza viruses hemagglutinin stalk domain. mBio 5:e00018-10. https://doi.org/10.1128/mBio.00018-10.

25. Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R. 2017. Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio 8:e00795-16. https://doi.org/10.1128/mBio.00795-16.

26. Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R. 2017. Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. mBio 8:e00795-16. https://doi.org/10.1128/mBio.00795-16.

27. Cervantes-Medina A, Taubenberger JK, Moro MJ. 2017. Evaluation of preexisting anti-hemagglutinin stalk antibody as a correlate of protection in a healthy volunteer challenge with influenza A/H1N1pdm virus. mBio 9:e02284-17. https://doi.org/10.1128/mBio.02284-17.

28. Carson LS, Cui J, Fang H, Gao Q, Gao Y, Kerst J, Albrecht RA, Palese P. 2018. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. https://doi.org/10.1128/mBio.00018-10.

29. McEnery S, Alford LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273. https://doi.org/10.1038/nsmb.1566.

30. Margine I, Paleo P, Krammer F. 2013. Expression of functional recombinant HA antibodies in humans and mice. J Virol 87:4728–4737. https://doi.org/10.1128/JVI.03509-12.

31. Nachbagauer R, Krammer F, Albrecht RA. 2018. A live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal influenza virus vaccines provides pro-
Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol 89:3610–3618. https://doi.org/10.1128/JVI.03099-14.

Kirchenbaum GA, Ross TM. 2014. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 28:71–76. https://doi.org/10.1016/j.coi.2014.02.005.

Sautto GA, Kirchenbaum GA, Ross TM. 2018. Towards a universal influenza vaccine: different approaches for one goal. Virol J 15:17. https://doi.org/10.1186/s12985-017-0918-y.

Schmitt N, Beeri R, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF. 2012. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 42:863–869. https://doi.org/10.1002/eji.201041225.

Bloom JD, Gong Li, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272–1275. https://doi.org/10.1126/science.1222908.

Alter G, Malenfant JM, Altfeld M. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15–22. https://doi.org/10.1016/j.jim.2004.08.008.

Smith P, DiLillo DJ, Bourzuras S, Li F, Ravetch JV. 2012. Mouse model recapitulating human Fc gamma receptor structural and functional diversity. Proc Natl Acad Sci U S A 109:6108–6113. https://doi.org/10.1073/pnas.1203954109.

Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. 2015. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis 212:1191–1199. https://doi.org/10.1093/infdis/jiv195.

Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P. 2016. Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner. mBio 7:e01624-16. https://doi.org/10.1128/mBio.01624-16.

World Health Organization. 2011. Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization, Geneva, Switzerland.

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, Ellebedy AH. 2018. Broadly-reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice from highly pathogenic H5N1 challenge. J Virol 92:e00949-18. https://doi.org/10.1128/JVI.00949-18.

Hoffmann E, Neumann G, Kawoaka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108–6113. https://doi.org/10.1073/pnas.100133697.